EUVIMEDEUVIMED entdecken
ÜbersichtsarbeitOpen Access · CC BY 4.0

Metabolomics in Thoracic Oncology from Biomarker Discovery to Therapeutic Targeting: A Narrative Review

Mohamed A Mahmoud, Gaurav Sharma iD, Inderpal S Sarkaria iD, Matthew R Porembka, Ralph J DeBerardinis iD, Kemp H Kernstine iD

Cancers · 07.11.2026 · 18 (21) · 3582

DOI: 10.3390/cancers18213582 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift Cancers, online erschienen am 07.11.2026. Verfasst von Mohamed A Mahmoud und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA. Die Arbeit nennt 101 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Thoracic malignancies show context-dependent metabolic plasticity that influences growth, immune evasion, and treatment response. This review examines how metabolomics, stable-isotope tracing, and metabolic flux analysis complement molecular profiling in lung, esophageal, pleural, and thymic cancers. We distinguish metabolite abundance from isotope enrichment and quantitative flux, and review analytical platforms, computational workflows, histology-specific programs, immunometabolism, biomarkers, and therapy. Lung squamous cell carcinoma often depends on glycolysis, lung adenocarcinoma shows substrate and spatial heterogeneity, and molecular subsets of small cell lung cancer have preclinical vulnerabilities in arginine metabolism and guanosine nucleotide synthesis. Hypoxia and metabolite exchange among malignant, stromal, and immune cells may shape therapeutic resistance. Biofluid and tissue studies support early detection and monitoring, but most circulating signatures and findings in rare thoracic tumors remain exploratory. Translation is limited by confounding, incomplete metabolite identification, small cohorts, and limited external validation. Trials of unselected metabolic inhibitors have largely failed. Two biomarker-selected strategies have advanced: arginine deprivation in non-epithelioid pleural mesothelioma, a population enriched for argininosuccinate synthetase 1 (ASS1) deficiency, and PRMT5 inhibition in tumors with MTAP deletion. These results suggest that success may depend on selecting patients by a demonstrated metabolic dependency rather than by the plausibility of the target. Progress requires harmonized multicenter workflows, paired tissue and biofluid sampling, rigorous validation, and integration with spatial, single-cell, multi-omic, and clinical data.

Schlagwörter

Stichwörter der Autor:innen

cancer metabolomicsmetabolic biomarkersmetabolic flux analysismetabolism-targeted therapyprecision oncologystable-isotope tracingthoracic oncologytumor microenvironment

Autor:innen und Institutionen

  • Department of Cardiovascular and Thoracic Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Department of Surgery, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Eugene McDermott Center for Human Growth and Development, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Children's Medical Center Research Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.
  • Howard Hughes Medical Institute, University of Texas Southwestern Medical Center, Dallas, TX 75390, USA.

ORCID-Profile: Gaurav Sharma, Inderpal S Sarkaria, Ralph J DeBerardinis, Kemp H Kernstine

Förderung

  • NCI NIH HHS

Zitieren

APA

Mahmoud, M. A., Sharma, G., Sarkaria, I. S., Porembka, M. R., DeBerardinis, R. J., & Kernstine, K. H. (2026). Metabolomics in Thoracic Oncology from Biomarker Discovery to Therapeutic Targeting: A Narrative Review. Cancers, 18(21), 3582. https://doi.org/10.3390/cancers18213582

Vancouver

Mahmoud MA, Sharma G, Sarkaria IS, Porembka MR, DeBerardinis RJ, Kernstine KH. Metabolomics in Thoracic Oncology from Biomarker Discovery to Therapeutic Targeting: A Narrative Review. Cancers. 2026;18(21):3582. doi:10.3390/cancers18213582

BibTeX
@article{Mahmoud2026,
  author = {Mahmoud, Mohamed A and Sharma, Gaurav and Sarkaria, Inderpal S and Porembka, Matthew R and DeBerardinis, Ralph J and Kernstine, Kemp H},
  title = {Metabolomics in Thoracic Oncology from Biomarker Discovery to Therapeutic Targeting: A Narrative Review},
  journal = {Cancers},
  year = {2026},
  volume = {18},
  number = {21},
  pages = {3582},
  doi = {10.3390/cancers18213582}
}
Kostenlos starten →